GlassScriptPhysician profile
Debasis H Sahoo
NPI 1376701458
$18,703.43
in general payments reported to CMS, 2019-2025
28 companies · $7,126 in 2025
The $7,126 reported for 2025 was more than what 91% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,345 · 2020: $195 · 2021: $632 · 2022: $2,940 · 2023: $1,189 · 2024: $3,277 · 2025: $7,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,088 · Food and Beverage: $3,499 · Consulting Fee: $1,836 · Education: $149 · Travel and Lodging: $19.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,088.00 |
| Food and Beverage | $3,499.44 |
| Consulting Fee | $1,836.00 |
| Education | $149.05 |
| Travel and Lodging | $19.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $9,129.99 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,103.01 | 2019-2025 | Ofev |
| Regeneron Healthcare Solutions, INC. | $2,551.32 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,357.04 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $316.59 | 2022-2025 | Tezspire |
| Astrazeneca Pharmaceuticals LP | $297.94 | 2020-2025 | Breztri, Airsupra, Tezspire |
| United Therapeutics Corporation | $258.20 | 2021-2025 | Tyvaso, Tyvaso |
| Baxter Healthcare | $256.04 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Merck Sharp & Dohme LLC | $194.14 | 2023-2025 | Winrevair, Zerbaxa, Dificid |
| Insmed, INC. | $181.22 | 2024-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $144.84 | 2022-2024 | Opsumit |
| Teva Pharmaceuticals USA, INC. | $143.46 | 2021-2022 | |
| Genentech USA, INC. | $137.14 | 2019 | |
| Mallinckrodt Enterprises LLC | $89.81 | 2019 | |
| Advanced Respiratory, INC | $88.17 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $73.01 | 2023-2024 | Qutenza |
| Abbvie INC. | $68.86 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $59.99 | 2023 | |
| Grt US Holding, INC. | $54.65 | 2022 | |
| Mylan Specialty L.P. | $42.35 | 2023-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $32.45 | 2025 | Glassia |
| Pfizer INC. | $22.67 | 2023 | |
| Abbott Laboratories | $20.63 | 2024 | Eterna |
| Mallinckrodt Hospital Products INC. | $18.77 | 2021 | |
| Viatris Specialty LLC | $17.35 | 2025 | Yupelri |
| Inogen, INC. | $16.13 | 2023 | Inogen |
| Z-Medica, LLC | $14.54 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $13.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debasis Sahoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.